View Older Stories View More Recent Stories
-
AstraZeneca agrees to lower US drug prices, delay tariffs
-
Trump: AstraZeneca is committing to discounts
-
AstraZeneca (AZN) to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
-
Astrazeneca (AZN) Strikes Deal With White House On Drug Prices - MSNBC
-
AstraZeneca to invest $4.5 billion in Virginia manufacturing facility
-
Turbine partners with AstraZeneca on AI-driven drug discovery platform
-
AstraZeneca's baxdrostat meets primary endpoint in resistant hypertension trial
-
AstraZeneca's baxdrostat meets primary endpoint in phase III trial
-
Acting CDC head Jim O’neill: I call on vaccine manufacturers to develop safe monovalent vaccines to replace the combined MMR - X post
-
DATROWAY shows survival benefit in triple-negative breast cancer trial
-
DATROWAY shows survival benefit for triple negative breast cancer
-
AstraZeneca (AZN) India - receives permission to import Enhertu
-
AstraZeneca (AZN) options active option volume of 36K contracts
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
-
ENHERTU shows improvement over T-DM1 in early breast cancer trial
-
Britain would face 100% tariffs on U.S. pharmaceuticals under latest Trump's plan - Reuters
-
EU will still have 15% pharma tariff, not 100% - Bloomberg
-
AstraZeneca launches direct-to-consumer platform for US patients
-
AstraZeneca's Enhertu gets FDA priority review for breast cancer
-
SOPHiA GENETICS expands AstraZeneca partnership for cancer detection
-
AstraZeneca (AZN) reports Koselugo recommended for approval in the EU by CHMP for plexiform neurofibromas in adults with neurofibromatosis type 1
-
AstraZeneca (AZN) reports Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps
-
AstraZeneca's SAPHNELO subcutaneous trial hits primary endpoint
-
AstraZeneca's Saphnelo shows positive results in lupus trial
-
AstraZeneca's Fasenra fails to meet primary endpoint in COPD trial
-
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP150.13 at Goldman Sachs
-
AstraZeneca (AZN) PT Raised to $4,925 at UBS
-
Make sure you own this pharma stock: BofA
-
Goldman Sachs Reiterates Conviction Buy Rating on AstraZeneca (AZN:LN) (AZN)
-
Jefferies Reiterates Hold Rating on Mineralys Therapeutics, Inc. (MLYS)
-
AstraZeneca launches home delivery service for nasal flu vaccine
-
SOPHiA GENETICS expands AstraZeneca partnership for AI breast cancer research
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
AstraZeneca (AZN) Tops Q2 EPS by 108c; reaffirms guidance
-
AstraZeneca receives FDA priority review for IMFINZI in gastric cancer
-
AstraZeneca (AZN) says Trixeo Aerosphere received positive EU CHMP opinion
-
AstraZeneca plans $50 billion US investment by 2030
-
AstraZeneca's TAGRISSO plus chemotherapy extends survival in lung cancer
-
ENHERTU plus pertuzumab gets FDA breakthrough therapy designation
-
AstraZeneca drug meets goals in hypertension trial
-
Summit Therapeutics (SMMT) Is Said In Talks For $15 Billion Partnership With Astra (AZN) - Bloomberg
-
AstraZeneca stock rises amid reports CEO favors US listing move
-
AstraZeneca (AZN) CEO Wants To Move Listing To US - The Times
-
AstraZeneca (AZN) says Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
-
AstraZeneca (AZN) enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research
-
UBS identifies stock winners amid structural growth tailwinds
-
Daiichi Sankyo, AstraZeneca (AZN): ENHERTU Plus Pertuzumab Reduced the Risk of Disease Progression or Death
-
AstraZeneca (AZN) Reports ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP
